Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax

Completed · Not applicable

Conditions studied: Sjogren's Disease

In brief

The purpose of this study is to evaluate the effects of an anti-inflammatory drug (Lotemax®) on the surface of the eye and tear film (a film that coats the eye which is made up of oil and water).

Key facts

Study ID

NCT02322528

Run by

University of Rochester

People needed

10

Starts

2014-04-01

Expected to finish

2015-08-01

Last updated by the study team

2015-10-16

Who can join

Age: 50 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 50-70
• Diagnosed with Sjogren's Disease
• Good general health (defined by medication use that has not changed within the last 2 months and the absence of medical conditions that are deemed confounding to the data as determined by the PI)
• Ability to give informed consent
• Willing to spend time for the study; approximately one hour for a screening visit and between 60-90 minutes for each of the measurement visits
• Either gender
• Any racial or ethnic origin

You may not qualify if…

• Use of any prescription ocular medication (such as but not limited to, glaucoma medications and Restasis) used within 14 days of the screening visit or started prior to the measurement visit(s).
• Current acute eye disease that affects the surface of the eye such as, but not limited to blepharitis, ocular allergy, and infection.
• Subjects who have had cataract surgery less than one year ago
• Use of soft or hard contact lenses.
• Female subjects may not be pregnant or lactating (subjects will be asked to self-report these conditions).
• Inability to provide analyzable data

Where it is running

• Flaum Eye Institute at the University of Rochester — Rochester, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.